658 filings
Page 3 of 33
6-K
9fzkx yoaio
31 Mar 23
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients
5:45pm
6-K
irvx0
30 Mar 23
Immutep Announces Expansion of Triple Combination Therapy
5:45pm
6-K
l4uw5masoo
14 Mar 23
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
6:05am
6-K
d5zl3ucxy68 m79xe2o
27 Feb 23
Half-Year Financial Report
12:00am
SC 13G/A
8jgkc
9 Feb 23
IMMUTEP / FIL ownership change
7:57am
6-K
gp3 ysqjy
6 Feb 23
Promising initial efficacy results showing a 72.7% response rate and 90.9% disease control rate reported at SITC 2022
5:04pm
6-K
p94x69
30 Jan 23
Immutep Quarterly Activities Report & Appendix 4C
7:03pm
6-K
7rh7cpwdc9hr
4 Jan 23
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
6:07am
6-K
d38g24
4 Jan 23
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
6:06am
6-K
d8ai y4sb
8 Dec 22
Immutep Successfully Achieves Commercial Scale in Manufacturing of
4:44pm
6-K
s0xrdgcxzfo11 r0qj
6 Dec 22
Achievement Allows IND-enabling Studies in 1H’2023 and Subsequent Clinical Testing of IMP761 to Address Root Cause of Autoimmune Diseases
8:48pm
6-K
c9fsb2u
29 Nov 22
Current report (foreign)
5:13pm
6-K
vdy954
14 Nov 22
Immutep receives Australian R&D Tax Incentive
5:55pm
6-K
3is vv8gy0ln0
14 Nov 22
Current report (foreign)
10:04am
6-K
jakm1hr chp
14 Nov 22
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its
10:03am
6-K
9mov7x
14 Nov 22
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
10:02am
6-K
si6e hi9etxprim5zo
9 Nov 22
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha
5:26pm
6-K
srvh7 vh2c6l
4 Nov 22
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected
5:06pm
6-K
efh4e2t36 l81w8sj
3 Nov 22
Immutep Late-Breaking Abstract Accepted for Oral Presentation
6:56pm